cobolimab
Selected indexed studies
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. (Clin Cancer Res, 2025) [PMID:40552935]
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. (Clin Cancer Res, 2025) [PMID:40552922]
- New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. (Curr Oncol Rep, 2022) [PMID:35218498]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. (2025) pubmed
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. (2025) pubmed
- New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. (2022) pubmed